Rituximab

Current status as therapy for malignant and Benign hematologic disorders

Nihal E. Abdulla, Mary J. Ninan, Avi Markowitz

    Research output: Contribution to journalArticle

    12 Citations (Scopus)

    Abstract

    Rituximab is a chimeric monoclonal antibody targeting the pan-B-cell antigen CD20 and was the first monoclonal antibody approved for clinical use in the treatment of cancer. Since its first approval by the FDA in 1997, investigators have continued to explore a variety of clinical conditions in which rituximab has proven effective with minimal toxicity. Rituximab, as monotherapy or in combination with chemotherapy, has been studied extensively in untreated and relapsedrefractory settings as both induction and maintenance therapy for the treatment of CD20-positive lymphomas and chronic lymphocytic leukemia, in addition to non-malignant hematologic disorders including autoimmune hemolytic anemia and immune thrombocytopenic purpura. Here we discuss the clinical development of rituximab with a review of the efficacy data from clinical trials and its current status in the practice of hematology and oncology.

    Original languageEnglish (US)
    Pages (from-to)71-82
    Number of pages12
    JournalBioDrugs
    Volume26
    Issue number2
    DOIs
    StatePublished - 2012

    Fingerprint

    CD20 Antigens
    Monoclonal Antibodies
    Autoimmune Hemolytic Anemia
    Idiopathic Thrombocytopenic Purpura
    Hematology
    B-Cell Chronic Lymphocytic Leukemia
    Therapeutics
    Combination Drug Therapy
    Lymphoma
    B-Lymphocytes
    Research Personnel
    Clinical Trials
    Rituximab
    Neoplasms

    Keywords

    • Chronic-lymphocytic-leukaemia
    • Diffuse-large-B-cell-lymphoma
    • Follicular-lymphoma
    • Haematological-disorders
    • Lymphoma
    • Rituximab

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Pharmacology
    • Biotechnology

    Cite this

    Rituximab : Current status as therapy for malignant and Benign hematologic disorders. / Abdulla, Nihal E.; Ninan, Mary J.; Markowitz, Avi.

    In: BioDrugs, Vol. 26, No. 2, 2012, p. 71-82.

    Research output: Contribution to journalArticle

    Abdulla, Nihal E. ; Ninan, Mary J. ; Markowitz, Avi. / Rituximab : Current status as therapy for malignant and Benign hematologic disorders. In: BioDrugs. 2012 ; Vol. 26, No. 2. pp. 71-82.
    @article{624d954dc3f941e491508848d3adb46d,
    title = "Rituximab: Current status as therapy for malignant and Benign hematologic disorders",
    abstract = "Rituximab is a chimeric monoclonal antibody targeting the pan-B-cell antigen CD20 and was the first monoclonal antibody approved for clinical use in the treatment of cancer. Since its first approval by the FDA in 1997, investigators have continued to explore a variety of clinical conditions in which rituximab has proven effective with minimal toxicity. Rituximab, as monotherapy or in combination with chemotherapy, has been studied extensively in untreated and relapsedrefractory settings as both induction and maintenance therapy for the treatment of CD20-positive lymphomas and chronic lymphocytic leukemia, in addition to non-malignant hematologic disorders including autoimmune hemolytic anemia and immune thrombocytopenic purpura. Here we discuss the clinical development of rituximab with a review of the efficacy data from clinical trials and its current status in the practice of hematology and oncology.",
    keywords = "Chronic-lymphocytic-leukaemia, Diffuse-large-B-cell-lymphoma, Follicular-lymphoma, Haematological-disorders, Lymphoma, Rituximab",
    author = "Abdulla, {Nihal E.} and Ninan, {Mary J.} and Avi Markowitz",
    year = "2012",
    doi = "10.2165/11599500-000000000-00000",
    language = "English (US)",
    volume = "26",
    pages = "71--82",
    journal = "BioDrugs",
    issn = "1173-8804",
    publisher = "Adis International Ltd",
    number = "2",

    }

    TY - JOUR

    T1 - Rituximab

    T2 - Current status as therapy for malignant and Benign hematologic disorders

    AU - Abdulla, Nihal E.

    AU - Ninan, Mary J.

    AU - Markowitz, Avi

    PY - 2012

    Y1 - 2012

    N2 - Rituximab is a chimeric monoclonal antibody targeting the pan-B-cell antigen CD20 and was the first monoclonal antibody approved for clinical use in the treatment of cancer. Since its first approval by the FDA in 1997, investigators have continued to explore a variety of clinical conditions in which rituximab has proven effective with minimal toxicity. Rituximab, as monotherapy or in combination with chemotherapy, has been studied extensively in untreated and relapsedrefractory settings as both induction and maintenance therapy for the treatment of CD20-positive lymphomas and chronic lymphocytic leukemia, in addition to non-malignant hematologic disorders including autoimmune hemolytic anemia and immune thrombocytopenic purpura. Here we discuss the clinical development of rituximab with a review of the efficacy data from clinical trials and its current status in the practice of hematology and oncology.

    AB - Rituximab is a chimeric monoclonal antibody targeting the pan-B-cell antigen CD20 and was the first monoclonal antibody approved for clinical use in the treatment of cancer. Since its first approval by the FDA in 1997, investigators have continued to explore a variety of clinical conditions in which rituximab has proven effective with minimal toxicity. Rituximab, as monotherapy or in combination with chemotherapy, has been studied extensively in untreated and relapsedrefractory settings as both induction and maintenance therapy for the treatment of CD20-positive lymphomas and chronic lymphocytic leukemia, in addition to non-malignant hematologic disorders including autoimmune hemolytic anemia and immune thrombocytopenic purpura. Here we discuss the clinical development of rituximab with a review of the efficacy data from clinical trials and its current status in the practice of hematology and oncology.

    KW - Chronic-lymphocytic-leukaemia

    KW - Diffuse-large-B-cell-lymphoma

    KW - Follicular-lymphoma

    KW - Haematological-disorders

    KW - Lymphoma

    KW - Rituximab

    UR - http://www.scopus.com/inward/record.url?scp=84857836534&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84857836534&partnerID=8YFLogxK

    U2 - 10.2165/11599500-000000000-00000

    DO - 10.2165/11599500-000000000-00000

    M3 - Article

    VL - 26

    SP - 71

    EP - 82

    JO - BioDrugs

    JF - BioDrugs

    SN - 1173-8804

    IS - 2

    ER -